Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8845MR)

This product GTTS-WQ8845MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8845MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2565MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ5126MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ6795MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ3615MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ5200MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ11340MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ11356MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ2324MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW